<p>基因编辑股票代表近年生物制药领域最大的投资趋势之一。</p>
<p>基因编辑领域采用先进技术编辑不同生物体的 DNA，从而为转变性治疗选择打开可能性。该领域中最流行的工具是 CRISPR-Cas9，因其在修改 DNA 方面的精准性、速度和成本效益而备受推崇。</p>
<p>然而，对于任何转变性技术，公司要实现盈亏平衡需要时间。因此，投资基因编辑股票存在风险，但未来可能获得多倍回报的前景令人难以忽视。投资者的吸引力并不一定在于即时回报，而更在于这些公司承诺的强劲增长潜力。</p>
<p>因此，以热情和谨慎的态度探索这个高风险领域至关重要。考虑到这一点，以下三家基因编辑股票完全符合要求，提供了可观的长期增长空间。</p>
<h2>买入的基因编辑股票：CRISPR 治疗（CRSP）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：rafapress / Shutterstock.com</p>
<p>瑞士生物科技公司 <strong>CRISPR 治疗</strong>（纳斯达克股票代码：<strong>CRSP</strong>）或许是基因编辑平台中最早的倡导者，旨在治疗罕见病和常见疾病。尽管公司仍处于无收入阶段，但今年情况可能会发生巨大变化。最近，该公司获得了其治疗镰状细胞病和依赖输血型β地中海贫血的突破性 Casgevy 疗法的绿灯。因此，分析师预计该公司今年的营收将达到 7.94 亿美元，到 2025 年将达到 3.307 亿美元。</p>
<p>CRSP 股票虽然表现疲软，年初至今已经下跌超过 12.8%。这在很大程度上与其自成立以来过去十年未能盈利有关。然而，过去几年公司经历了许多事件，走上了全新的轨迹。它正在推进一个有前景的疗法管线，针对各种疾病，从血液疾病到癌症和糖尿病，为其带来了爆炸性增长的机会。</p>
<h2>福泰制药（VRTX）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Pavel Kapysh / Shutterstock.com</p>
<p><strong>福泰制药</strong>（纳斯达克股票代码：<strong>VRTX</strong>）是生物技术领域中最资深的参与者之一。与基因编辑领域的一大批初创公司不同，福泰制药在制药领域拥有丰富的历史，使其能够利用其庞大的财务资源。</p>
<p>近年来，我们看到它涉足新领域，如基因编辑，针对炎症性和自身免疫性疾病以及某些癌症。此外，它与 CRISPR 治疗合作开发 Casgevy 疗法，正如前文所述，具有巨大的长期潜力。</p>
<p>福泰制药的财务状况非常良好，拥有出色的利润率和不断增长的销售额。令人印象深刻的是，在最近的一个季度，销售额同比增长了 13.3%。展望 2024 财年，分析师预计该公司的销售额将达到 107.5 亿美元，较上一年增长 16.6%。考虑到这些数据，当前水平下的 VRTX 股票难以忽视。</p>
<h2>Beam Therapeutics（BEAM）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：luchschenF / Shutterstock.com</p>
<p><strong>Beam Therapeutics</strong>（纳斯达克股票代码：<strong>BEAM</strong>）是基因编辑领域的另一家新兴初创公司，凭借其新颖的主要编辑技术结合 CRISPR 技术而引起轰动。其创新方法有助于对基因的特定部分进行精确调整，而不是完全基因替换。因此，该公司仍处于一个充满巨大潜力的领域的前沿，使其成为一个引人注目的生物制药前景。</p>
<p>其旗舰药物 BEAM-302 突显了主要编辑的有效性，精准地针对严重的α-1 抗胰蛋白酶缺乏症（AATD）的直接原因。此外，从财务角度看，Beam 处于稳健地位，最近一个季度以 12 亿美元现金结算，预计资金运营将持续到 2027 年。因此，作为该领域新兴参与者，Beam 在推动医学科学边界的同时，为未来提供巨大的长期增长空间。此外，华尔街对该股给予一致的 “买入” 评级，预计从当前水平上涨 59%。</p>
<p><em>在发布日期，Muslim Farooque 在本文中提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，受 InvestorPlace.com 发布指南约束</em></p>
<p><em>在发布日期，负责编辑在本文中提到的证券中没有（直接或间接）任何头寸</em></p>
<p>Muslim Farooque 是一位热心的投资者和乐观主义者。作为一名终身游戏玩家和科技爱好者，他特别喜欢分析科技股。Muslim 拥有牛津布鲁克斯大学应用会计学学士学位。</p>

CRISPR治疗

BEAM

福泰制药

<p>基因编辑股票是生物制药领域的热门投资趋势。CRISPR 治疗、福泰制药和 Beam Therapeutics 是三家提供长期增长潜力的公司。CRISPR 治疗正在开发针对各种疾病的治疗方案，并预计实现显著的收入增长。福泰制药具有强大的财务实力，并与 CRISPR 治疗展开合作。Beam Therapeutics 是一家新兴初创公司，拥有创新的主编辑技术。这些股票具有高回报潜力，但也伴随着风险</p>

<p>Gene editing stocks represent one of the biggest investing trends in biopharma in recent years.</p>
<div class="lb-trans"><p>基因编辑股票代表近年生物制药领域最大的投资趋势之一。</p>
</div><p>The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options. The most popular tool in the niche is CRISPR-Cas9, which has been touted for its precision, speed, and cost-effectiveness in modifying DNA.</p>
<div class="lb-trans"><p>基因编辑领域采用先进技术编辑不同生物体的 DNA，从而为转变性治疗选择打开可能性。该领域中最流行的工具是 CRISPR-Cas9，因其在修改 DNA 方面的精准性、速度和成本效益而备受推崇。</p>
</div><p>However, with any transformative technology, breaking even takes time for companies. Therefore, investing in gene editing stocks has its risks, but the prospect of multi-bagger returns down the road is tough to ignore. The lure for investors doesn’t necessarily lie in immediate returns but rather in the robust growth potential these firms promise.</p>
<div class="lb-trans"><p>然而，对于任何转变性技术，公司要实现盈亏平衡需要时间。因此，投资基因编辑股票存在风险，但未来可能获得多倍回报的前景令人难以忽视。投资者的吸引力并不一定在于即时回报，而更在于这些公司承诺的强劲增长潜力。</p>
</div><p>Therefore, it’s critical to approach this high-stakes realm with a mix of enthusiasm and caution. With that in mind, these three gene editing stocks fit the bill perfectly, offering substantial long-term upside.</p>
<div class="lb-trans"><p>因此，以热情和谨慎的态度探索这个高风险领域至关重要。考虑到这一点，以下三家基因编辑股票完全符合要求，提供了可观的长期增长空间。</p>
</div><h2>Gene Editing Stocks To Buy: Crispr Therapeutics (CRSP)</h2>
<div class="lb-trans"><h2>买入的基因编辑股票：CRISPR 治疗（CRSP）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: rafapress / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：rafapress / Shutterstock.com</p>
</div><p>Swiss biotech <strong>Crispr Therapeutics</strong>(NASDAQ: <strong>CRSP</strong>) is perhaps the earliest exponent of gene editing platforms, looking to target both rare and common diseases. Though it’s still in the pre-revenue stages, things will likely change dramatically this year. It recently got the green signal for its groundbreaking Casgevy therapy for treating sickle cell disease and transfusion-dependent beta-thalassemia. Consequently, analysts expect the firm to post $79.4 million in revenues this year and a whopping $330.7 million in 2025.</p>
<div class="lb-trans"><p>瑞士生物科技公司 <strong>CRISPR 治疗</strong>（纳斯达克股票代码：<strong>CRSP</strong>）或许是基因编辑平台中最早的倡导者，旨在治疗罕见病和常见疾病。尽管公司仍处于无收入阶段，但今年情况可能会发生巨大变化。最近，该公司获得了其治疗镰状细胞病和依赖输血型β地中海贫血的突破性 Casgevy 疗法的绿灯。因此，分析师预计该公司今年的营收将达到 7.94 亿美元，到 2025 年将达到 3.307 亿美元。</p>
</div><p>CRSP stock, though, has been laggard, having shed more than 12.8% of its value year-to-date (YTD). Much of this is linked to its inability to generate profits over the past decade since its inception. However, the past couple of years have been eventful, with the firm on a completely new trajectory. It’s advancing a promising pipeline of therapies targeting a variety of conditions, from blood diseases to cancer and diabetes, positioning it for explosive growth.</p>
<div class="lb-trans"><p>CRSP 股票虽然表现疲软，年初至今已经下跌超过 12.8%。这在很大程度上与其自成立以来过去十年未能盈利有关。然而，过去几年公司经历了许多事件，走上了全新的轨迹。它正在推进一个有前景的疗法管线，针对各种疾病，从血液疾病到癌症和糖尿病，为其带来了爆炸性增长的机会。</p>
</div><h2>Vertex Pharmaceuticals (VRTX)</h2>
<div class="lb-trans"><h2>福泰制药（VRTX）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Pavel Kapysh / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：Pavel Kapysh / Shutterstock.com</p>
</div><p><strong>Vertex Pharmaceuticals</strong>(NASDAQ: <strong>VRTX</strong>) stands out as one of the most seasoned players in the biotech space. Unlike the sea of start-ups in the gene editing field, Vertex boasts a rich legacy in the pharma space, empowering it to leverage its massive financial resources.</p>
<div class="lb-trans"><p><strong>福泰制药</strong>（纳斯达克股票代码：<strong>VRTX</strong>）是生物技术领域中最资深的参与者之一。与基因编辑领域的一大批初创公司不同，福泰制药在制药领域拥有丰富的历史，使其能够利用其庞大的财务资源。</p>
</div><p>In recent years, we’ve seen it dabbling into new areas like gene editing, targeting inflammatory and autoimmune disorders along with certain cancers. Moreover, it collaborated with Crispr Therapeutics on the development of the Casgevy therapy, which holds immense long-term potential as discussed earlier.</p>
<div class="lb-trans"><p>近年来，我们看到它涉足新领域，如基因编辑，针对炎症性和自身免疫性疾病以及某些癌症。此外，它与 CRISPR 治疗合作开发 Casgevy 疗法，正如前文所述，具有巨大的长期潜力。</p>
</div><p>Vertex’s financials are in excellent shape, backed by a superb margin profile and growing sales. Impressively, in its most recent quarter sales were up a heartening 13.3% year-over-year (YOY). Looking ahead to fiscal 2024, analysts expect the firm to post $10.75 billion in sales, marking a healthy 16.6% jump from the previous year. With these figures in play, VRTX stock is tough to ignore at current levels.</p>
<div class="lb-trans"><p>福泰制药的财务状况非常良好，拥有出色的利润率和不断增长的销售额。令人印象深刻的是，在最近的一个季度，销售额同比增长了 13.3%。展望 2024 财年，分析师预计该公司的销售额将达到 107.5 亿美元，较上一年增长 16.6%。考虑到这些数据，当前水平下的 VRTX 股票难以忽视。</p>
</div><h2>Beam Therapeutics (BEAM)</h2>
<div class="lb-trans"><h2>Beam Therapeutics（BEAM）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: luchschenF / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：luchschenF / Shutterstock.com</p>
</div><p><strong>Beam Therapeutics</strong> (NASDAQ: <strong>BEAM</strong>) is another emerging startup in the gene editing arena that’s making waves with its novel prime editing techniques paired with CRISPR technology. Its innovative approach facilitates precise adjustments to specific parts of genes instead of a complete genetic replacement. Hence, the firm remains at the forefront of a sector brimming with tremendous potential, making it a compelling biopharma prospect.</p>
<div class="lb-trans"><p><strong>Beam Therapeutics</strong>（纳斯达克股票代码：<strong>BEAM</strong>）是基因编辑领域的另一家新兴初创公司，凭借其新颖的主要编辑技术结合 CRISPR 技术而引起轰动。其创新方法有助于对基因的特定部分进行精确调整，而不是完全基因替换。因此，该公司仍处于一个充满巨大潜力的领域的前沿，使其成为一个引人注目的生物制药前景。</p>
</div><p>Its flagship drug, BEAM-302, underscores the effectiveness of prime editing, targeting the direct cause of severe alpha-1 antitrypsin deficiency (AATD) with incredible precision. Also, from a financial perspective, Beam stands on robust ground, ending its most recent quarter with $1.2 billion in cash, as it projects funding operations through 2027. Hence, as an up-and-coming player in the niche, Beam continues pushing the boundaries of medical science while offering tremendous long-term upside ahead. Moreover, Wall Street assigns a consensus ‘buy’ rating to the stock, forecasting a 59% upside from current levels.</p>
<div class="lb-trans"><p>其旗舰药物 BEAM-302 突显了主要编辑的有效性，精准地针对严重的α-1 抗胰蛋白酶缺乏症（AATD）的直接原因。此外，从财务角度看，Beam 处于稳健地位，最近一个季度以 12 亿美元现金结算，预计资金运营将持续到 2027 年。因此，作为该领域新兴参与者，Beam 在推动医学科学边界的同时，为未来提供巨大的长期增长空间。此外，华尔街对该股给予一致的 “买入” 评级，预计从当前水平上涨 59%。</p>
</div><p><em>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines</em></p>
<div class="lb-trans"><p><em>在发布日期，Muslim Farooque 在本文中提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，受 InvestorPlace.com 发布指南约束</em></p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or</em></p>
<p><em>indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在发布日期，负责编辑在本文中提到的证券中没有（直接或间接）任何头寸</em></p>
</div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor’s of science degree in applied accounting from Oxford Brookes University.</p>
<div class="lb-trans"><p>Muslim Farooque 是一位热心的投资者和乐观主义者。作为一名终身游戏玩家和科技爱好者，他特别喜欢分析科技股。Muslim 拥有牛津布鲁克斯大学应用会计学学士学位。</p>
</div>

3 只基因编辑股票正在塑造医学的未来